CALIFORNIA - A company that developed a blood test that detects dozens of types of cancer has acknowledged that about 400 of its customers were mistakenly told in May that they might have the disease.
The problem was not caused by inaccurate test results, Grail said. More than half of the people who received the letter in error had not yet had their blood drawn for the test, the company said. “No patient health information has been disclosed or breached due to this issue, and no patient harm or adverse events have been reported,” it said.
The test-result letters were erroneously sent out amid a regulatory battle between the United States and Grail’s parent company, Illumina, the leading maker of gene-sequencing machines. Illumina acquired Grail in August 2021.